Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554747 | 1.00 | KMT2A (0.56) | KMT2AABCG2NR4A2TTRPLA2G4B | |
| SCHEMBL13554687 | 1.00 | KMT2A (0.56) | KMT2AABCG2NR4A2TTRPLA2G4B | |
| SCHEMBL25362791 | 0.88 | MAOB (0.50) | KMT2AABCG2 | |
| SCHEMBL29649612 | 0.88 | MAOB (0.50) | KMT2AABCG2 | |
| SCHEMBL14649336 | 0.86 | ABCG2 (0.55) | KMT2AABCG2POLB | |
| SCHEMBL13554738 | 0.86 | ABCG2 (0.55) | KMT2AABCG2POLB | |
| SCHEMBL19665046 | 0.86 | KMT2A (0.73) | KMT2ANR4A2PLA2G4BNR1H4POLB | |
| SCHEMBL13554748 | 0.83 | PKM (0.57) | ABCG2PLA2G4BPKM | |
| SCHEMBL17618288 | 0.81 | MEN1 (0.49) | KMT2APOLB | |
| SCHEMBL13554764 | 0.81 | MEN1 (0.49) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188727-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188727-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | CD4, HAVCR2, CD2 | KMT2A 3050/4885ABCG2 1072/4885NR4A2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.